Zheng Quan Zhi Xing·2025-03-25 13:54Core Viewpoint - The report evaluates the performance of Ernst & Young Huaming in auditing Shanghai Fosun Pharmaceutical Group Co., Ltd. for the fiscal year 2024, highlighting the firm's qualifications, service quality, and compliance with regulatory standards [1][9]. Group 1: Qualifications - Ernst & Young Huaming was established in September 1992 and transitioned to a special general partnership in August 2012, with its headquarters located in Beijing [1]. - As of December 31, 2023, the firm has 251 partners and over 1,700 certified public accountants, with more than 24.38 billion RMB in revenue from securities-related services [2]. Group 2: Service and Quality Management - The firm audited 137 A-share listed companies in 2023, generating a total audit fee of 9.05 billion RMB, primarily from sectors such as manufacturing, finance, and real estate [2]. - Ernst & Young Huaming has established a comprehensive quality management system that adheres to both national and international standards, ensuring effective implementation of quality management measures [4][6]. Group 3: Risk Management and Information Security - The firm has a robust risk management framework, including a professional opinion divergence resolution mechanism and a consultation memorandum system to document significant issues [5][6]. - Information security management responsibilities are clearly defined in the engagement contract, with systematic controls for document management and confidentiality [7][8]. Group 4: Audit Execution and Communication - Ernst & Young Huaming has dedicated audit teams with extensive experience in the pharmaceutical industry, ensuring tailored audit plans that meet the company's specific needs [6]. - The firm effectively communicated with the company's management regarding audit plans, risk assessments, and findings, resulting in a standard unqualified audit report [9].